AUS
NZ
UK
CA
USA
IND
Highlights
- ImmuPharma (IMM) stock price surged 27.6% on Saturday.
- Trading volume reached 8,992,934 shares, marking a 61% decrease from the average.
- The company specializes in peptide-based therapeutics for autoimmune diseases.
ImmuPharma plc (LON:IMM) experienced a notable 27.6% rise in its stock price during trading on Saturday. The stock peaked at GBX 3.60 before settling at GBX 3.35. This increase follows a previous closing of GBX 2.63, signaling a significant jump in investor sentiment. Despite the price hike, the trading volume of 8,992,934 shares was 61% lower than the average daily volume of 23,308,711 shares, suggesting a reduction in overall trading activity compared to usual sessions. This movement reflects trends seen in the broader LON healthcare stocks sector.
ImmuPharma's Stock Performance and Financials
ImmuPharma's market capitalization now stands at £13.95 million. The company is currently facing a price-to-earnings (P/E) ratio of -335.00, reflecting the challenges associated with its financial profile. With a beta of 1.53, the stock exhibits higher volatility compared to the market. The company’s 50-day simple moving average is GBX 1.59, while its 200-day moving average is GBX 1.69, indicating some upward momentum in recent trading sessions.
About ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company's portfolio includes novel treatments aimed at autoimmune diseases and anti-infectives. One of its lead programs, P140 (Lupuzor™), is a first-in-class autophagy immunomodulator intended for the treatment of Lupus. Preclinical studies also suggest the potential for therapeutic activity in other autoimmune diseases that share a similar mechanism of action.
